GQ-303

**GQ-303** is a preclinical, locally administered helper-dependent adenoviral gene therapy developed for osteoarthritis. The vector is designed for intra-articular injection and expresses proteoglycan 4, also known as lubricin, to improve joint lubrication and suppress molecular processes associated with pain, inflammation, and cartilage degeneration. ([bionity.com](https://www.bionity.com/en/news/1169616/advance-gene-therapy-pipeline-for-musculoskeletal-diseases.html)) GeneQuine Biotherapeutics originated the program, later renamed GQ Bio Therapeutics, which Pacira acquired in February 2025 along with its preclinical gene-therapy portfolio. ([healthcapital.de](https://www.healthcapital.de/en/news/article/genequine-biotherapeutics-changes-name-to-gq-bio-therapeutics-expands-facilities-and-appoints-industry-veteran-to-board/))